Drug price cuts in Spain will see pharmaceutical market decline, says BMI
Spain is ranked eighth, of the 10 countries surveyed in the Western European region in Business Monitor International’s Business Environment Ratings (BER) for first-quarter 2011.
The country has improved its position by one place and now ranks above both Italy and Portugal. However, while Spain offers positives for investors, such as its large drug market, it also holds various downsides, such as low population growth, cumbersome bureaucracy, provincial differences regarding drug regulation and reimbursement, and modest forecast market expansion due to cost-containment measures.
Globally, Spain's pharmaceutical market is rated 19th, having previously been 20th, out of the total of 83 countries surveyed. In the coming quarters, the wide-ranging price reductions and patent expirations will conspire to keep Spain towards the bottom of the regional BER matrix.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze